AMRI and Ono Broaden SMARTSOURCING™ Collaboration

              AMRI and Ono Broaden SMARTSOURCING™ Collaboration

  PR Newswire

  ALBANY, New York, April 23, 2013

- New Agreement Extends Drug Discovery and Development Collaboration Between
the Companies 

ALBANY, New York, April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI)
announced today that it has entered into a new five-year service agreement
with Ono Pharmaceutical Company, Ltd., (TSE: 4528), a pharmaceutical company
headquartered in Osaka, Japan. Under the terms of the agreement, AMRI may
provide a range of services from early drug discovery to cGMP manufacturing.

(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO )

The two companies have already agreed to medicinal chemistry projects within
the new framework to collaborate on additional hit-to-lead and lead
optimization for two new molecules, with the work to take place at AMRI's
medicinal chemistry laboratories in Albany, N.Y.

An early adopter of the AMRI SMARTSOURCING™ concept, Ono has been utilizing
AMRI's integrated global facilities and capabilities for projects ranging from
early drug discovery, including high-throughput screening (HTS), biology
support and computer-aided drug discovery (CADD), to multiple medicinal
chemistry programs and a variety of drug development and cGMP programs.

Thomas E. D'Ambra, Ph.D., Chairman, President and CEO of AMRI said, "We are
pleased to extend and broaden our service agreement with Ono. During the past
few years, Ono has become a very important client for AMRI and we would like
to acknowledge the deepening relationship between our companies. Our project
management teams and the scientists on all the Ono projects, from Singapore to
the United States, enjoy working with our counterparts at Ono and they are a
valuable customer and partner."

Louis Garguilo, Vice President of Business Development, said, "SMARTSOURCING™
is an industry leading movement to strategic decision making and the true
measurement of results and success in drug discovery, development and
manufacturing. Over the years, our relationship with Ono has grown based on
this type of value-added collaboration. We are also happy to announce this
expanding relationship in conjunction with the 2013 Biotechnology Industry
Organization (BIO) International Convention in Chicago, at the one-year
anniversary of our re-branding launch of AMRI SMARTSOURCING™ at this very show
last year in Boston."

Kazuhito Kawabata, Ph.D., Member of the Board of Directors, Executive Officer
and Executive Director, Discovery and Research of Ono, said, "We appreciate
AMRI's integrated capabilities and global reach, and believe that they are the
partner of choice to mutually work toward the best decisions and outcomes for
many of our projects. We look forward to continuing our relationship across
the drug discovery and development areas."

About AMRI

Albany Molecular Research, Inc. (AMRI) is a global contract research and
manufacturing organization offering customers fully integrated drug discovery,
development, and manufacturing services for over 21 years. AMRI has
demonstrated its adaptability as the pharmaceutical and biotechnology
industries have undergone tremendous change in response to regulatory and
market challenges. This experience, a track record of success and locations in
the United States, Europe and Asia now provides our customers with
SMARTSOURCING™, a full range of value-added opportunities providing customers
informed decision-making, enhanced efficiency and more successful outcomes at
all stages of the pipeline. AMRI has also successfully partnered R&D programs
and is actively seeking to out-license its remaining programs for further
development. For more information, please visit us at www.amriglobal.com .

Website: http://www.amriglobal.com
Contact: Investors - Michael Nolan, AMRI Chief Financial Officer,
518-512-2261, or Media - Gina Monari, AMRI Communications, 518-512-2512